Kura Oncology Inc (KURA)

Name: Kura Oncology Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-03-31

Latest Quarter

2025-03-31

Revenue

$14.1M

Net Income

-$57.4M

Operating Margin

-458.6%

Free Cash Flow

-$70.7M

Debt / Assets

76.4%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Kura Oncology Inc (KURA).
Income Statement (Quarterly)	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Revenue	14,108,000	53,883,000	0	0
Cost of Revenue	0	204,000	0	202,000
Gross Profit	14,108,000	53,679,000	0	-202,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	22,835,000	24,071,000	18,179,000	16,475,000
Operating Expenses	78,808,000	76,338,000	59,884,000	56,202,000
Operating Income	-64,700,000	-22,455,000	-59,884,000	-56,404,000
Interest Expense	0	403,000	412,000	406,000
Income Before Tax	-57,203,000	-17,199,000	-54,404,000	-50,837,000
Income Tax Expense	226,000	2,018,000	0	0
Net Income	-57,429,000	-19,217,000	-54,404,000	-50,837,000
Per Share
EPS	-0.66	-0.22	-0.63	-0.59
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Kura Oncology Inc (KURA).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	67,482,000	53,883,000	0	0	0
Cost of Revenue	57,000	848,000	849,000	759,000	0
Gross Profit	67,425,000	53,035,000	-849,000	-759,000	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	119,982,000	77,111,000	50,569,000	47,053,000	46,537,000
Operating Expenses	371,056,000	247,078,000	165,804,000	139,865,000	131,258,000
Operating Income	-303,631,000	-193,195,000	-165,804,000	-140,624,000	-131,258,000
Interest Expense	1,512,000	1,619,000	1,549,000	229,000	414,000
Income Before Tax	-278,369,000	-171,965,000	-152,631,000	-135,840,000	-130,466,000
Income Tax Expense	297,000	2,018,000	0	229,000	0
Net Income	-278,666,000	-173,983,000	-152,631,000	-136,069,000	-130,466,000
Per Share
EPS	-3.18	-2.02	-2.08	-2.03	-1.97
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Kura Oncology Inc (KURA).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	149,099,000	224,462,000	37,318,000	51,802,000
Short Term Investments	518,141,000	502,933,000	386,639,000	386,183,000
Net Receivables	12,604,000	6,100,000	0	0
Inventory	413,000	0	0	0
Total Current Assets	708,663,000	744,829,000	432,481,000	446,426,000
Property Plant Equipment	15,157,000	7,485,000	8,852,000	6,382,000
Goodwill and Intangibles	0	0	0	0
Total Assets	738,363,000	760,159,000	448,935,000	456,306,000
Liabilities
Account Payables	5,017,000	1,469,000	2,300,000	1,533,000
Short Term Debt	1,277,000	6,369,000	3,012,000	2,318,000
Total Current Liabilities	116,974,000	78,712,000	35,263,000	24,057,000
Long Term Debt	19,180,000	12,106,000	15,694,000	11,706,000
Total Liabilities	564,228,000	346,519,000	51,662,000	36,028,000
Shareholders Equity
Retained Earnings	-1,174,088,000	-895,422,000	-721,439,000	-568,808,000
Total Shareholders Equity	174,135,000	413,640,000	397,273,000	-568,808,000

Balance sheet annual history for Kura Oncology Inc (KURA).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	149,099,000	224,462,000	37,318,000	51,802,000	90,672,000
Short Term Investments	518,141,000	502,933,000	386,639,000	386,183,000	427,288,000
Net Receivables	12,604,000	6,100,000	0	0	0
Inventory	413,000	0	0	0	0
Total Current Assets	708,663,000	744,829,000	432,481,000	446,426,000	522,289,000
Property Plant Equipment	15,157,000	7,485,000	8,852,000	6,382,000	8,246,000
Goodwill and Intangibles	0	0	0	0	0
Total Assets	738,363,000	760,159,000	448,935,000	456,306,000	534,051,000
Liabilities
Account Payables	5,017,000	1,469,000	2,300,000	1,533,000	3,236,000
Short Term Debt	1,277,000	6,369,000	3,012,000	2,318,000	2,263,000
Total Current Liabilities	116,974,000	78,712,000	35,263,000	24,057,000	22,455,000
Long Term Debt	19,180,000	12,106,000	15,694,000	11,706,000	4,612,000
Total Liabilities	564,228,000	346,519,000	51,662,000	36,028,000	27,442,000
Shareholders Equity
Retained Earnings	-1,174,088,000	-895,422,000	-721,439,000	-568,808,000	-432,968,000
Total Shareholders Equity	174,135,000	413,640,000	397,273,000	-568,808,000	506,609,000

Cash flow quarterly history for Kura Oncology Inc (KURA).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-278,666,000	-173,983,000	-152,631,000	-135,840,000
Depreciation & Amortization	-7,456,000	848,000	849,000	759,000
Stock Based Compensation	37,108,000	33,897,000	28,082,000	26,318,000
Change in Working Capital	184,441,000	286,173,000	7,819,000	-2,982,000
Operating Cash Flow	-64,058,000	134,317,000	-124,824,000	-110,062,000
Investing Activities
Capital Expenditure	-6,638,000	-472,000	-168,000	-626,000
Investments	-6,638,000	-472,000	-168,000	-626,000
Investing Cash Flow	-13,098,000	-101,590,000	15,557,000	32,627,000
Financing Activities
Debt Repayment	0	0	0	-9,425,000
Common Stock Issued/Repurchased	1,793,000	145,813,000	94,783,000	24,721,000
Dividends Paid	0	0	0	0
Financing Cash Flow	1,793,000	154,417,000	94,783,000	38,565,000
Summary
Free Cash Flow	-70,696,000	133,845,000	-124,992,000	-110,688,000
Net Change in Cash	-75,363,000	187,144,000	-14,484,000	-38,870,000

Cash flow annual history for Kura Oncology Inc (KURA).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	-278,666,000	-173,983,000	-152,631,000	-135,840,000	-130,466,000
Depreciation & Amortization	-7,456,000	848,000	849,000	759,000	558,000
Stock Based Compensation	37,108,000	33,897,000	28,082,000	26,318,000	23,579,000
Change in Working Capital	184,441,000	286,173,000	7,819,000	-2,982,000	-3,224,000
Operating Cash Flow	-64,058,000	134,317,000	-124,824,000	-110,062,000	-104,551,000
Investing Activities
Capital Expenditure	-6,638,000	-472,000	-168,000	-626,000	-1,147,000
Investments	-6,638,000	-472,000	-168,000	-626,000	-1,147,000
Investing Cash Flow	-13,098,000	-101,590,000	15,557,000	32,627,000	-126,835,000
Financing Activities
Debt Repayment	0	0	0	-9,425,000	-7,250,000
Common Stock Issued/Repurchased	1,793,000	145,813,000	94,783,000	24,721,000	4,426,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	1,793,000	154,417,000	94,783,000	38,565,000	-3,435,000
Summary
Free Cash Flow	-70,696,000	133,845,000	-124,992,000	-110,688,000	-105,698,000
Net Change in Cash	-75,363,000	187,144,000	-14,484,000	-38,870,000	-234,821,000